Biogen Inc.

195.52-7.38-3.64%Vol 823.14K1Y Perf -27.80%
May 18th, 2022 15:51 DELAYED
BID195.51 ASK195.59
Open201.05 Previous Close202.90
Pre-Market198.26 After-Market-
 -4.64 -2.29%  - -
Target Price
271.18 
Analyst Rating
Moderate Buy 2.09
Potential %
38.55 
Finscreener Ranking
★+     43.09
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★+     49.04
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★★     51.89
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
2.97 
Earnings Rating
Sell
Market Cap28.63B 
Earnings Date
3rd May 2022
Alpha-0.00 Standard Deviation0.10
Beta0.42 

Today's Price Range

195.46201.77

52W Range

187.16468.55

5 Year PE Ratio Range

7.1032.60

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
6.19%
1 Month
-4.54%
3 Months
-3.28%
6 Months
-20.99%
1 Year
-27.80%
3 Years
-11.51%
5 Years
-19.74%
10 Years
54.20%

TickerPriceChg.Chg.%
BIIB195.52-7.3800-3.64
AAPL140.55-8.6950-5.83
GOOG2 252.97-81.0625-3.47
MSFT254.13-12.0700-4.53
XOM90.44-1.6700-1.81
WFC42.10-1.6150-3.69
JNJ175.34-3.4800-1.95
FB192.41-10.2150-5.04
GE75.12-1.2850-1.68
JPM119.78-2.4000-1.96
Financial StrengthValueIndustryS&P 500US Markets
1.50
2.00
0.37
0.67
7.60
Leverage Ratio 2.20
ProfitabilityValueIndustryS&P 500US Markets
77.00
17.40
25.20
37.50
14.08
RevenueValueIndustryS&P 500US Markets
10.82B
73.88
-7.70
-0.75
Earnings HistoryEstimateReportedSurprise %
Q01 20224.413.62-17.91
Q04 20213.323.392.11
Q03 20214.154.7714.94
Q02 20214.575.6824.29
Q01 20215.065.345.53
Q04 20204.934.58-7.10
Q03 20208.068.849.68
Q02 20208.0310.2627.77
Earnings Per EndEstimateRevision %Trend
6/2022 QR4.11-1.67Negative
9/2022 QR3.934.24Positive
12/2022 FY15.430.33Positive
12/2023 FY16.440.00-
Next Report Date-
Estimated EPS Next Report4.41
Estimates Count29
EPS Growth Next 5 Years %10.40
Volume Overview
Volume823.14K
Shares Outstanding146.45K
Shares Float129.76M
Trades Count20.30K
Dollar Volume162.97M
Avg. Volume1.02M
Avg. Weekly Volume907.85K
Avg. Monthly Volume1.10M
Avg. Quarterly Volume1.06M

Biogen Inc. (NASDAQ: BIIB) stock closed at 202.9 per share at the end of the most recent trading day (a 2.28% change compared to the prior day closing price) with a volume of 628.11K shares and market capitalization of 28.63B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 9100 people. Biogen Inc. CEO is Michel Vounatsos.

The one-year performance of Biogen Inc. stock is -27.8%, while year-to-date (YTD) performance is -15.43%. BIIB stock has a five-year performance of -19.74%. Its 52-week range is between 187.16 and 468.55, which gives BIIB stock a 52-week price range ratio of 2.97%

Biogen Inc. currently has a PE ratio of 20.40, a price-to-book (PB) ratio of 2.59, a price-to-sale (PS) ratio of 2.69, a price to cashflow ratio of 9.70, a PEG ratio of 2.32, a ROA of 6.28%, a ROC of 8.77% and a ROE of 13.59%. The company’s profit margin is 14.08%, its EBITDA margin is 25.20%, and its revenue ttm is $10.82 Billion , which makes it $73.88 revenue per share.

Of the last four earnings reports from Biogen Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $4.41 for the next earnings report. Biogen Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Biogen Inc. is Moderate Buy (2.09), with a target price of $271.18, which is +38.55% compared to the current price. The earnings rating for Biogen Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Biogen Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Biogen Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.35, ATR14 : 6.96, CCI20 : -30.96, Chaikin Money Flow : -0.24, MACD : -3.69, Money Flow Index : 43.65, ROC : -2.19, RSI : 49.13, STOCH (14,3) : 57.00, STOCH RSI : 1.00, UO : 51.32, Williams %R : -43.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Biogen Inc. in the last 12-months were: Alfred W. Sandrock (Sold 15 344 shares of value $6 751 360 ), Brian S. Posner (Sold 720 shares of value $197 402 ), Chirfi Guindo (Option Excercise at a value of $0), Chirfi Guindo (Sold 6 174 shares of value $2 716 560 ), Ginger Gregory (Option Excercise at a value of $0), Michael R. Mcdonnell (Option Excercise at a value of $2 031 130), Michel Vounatsos (Option Excercise at a value of $0), Nicole Murphy (Option Excercise at a value of $0), Rachid Izzar (Option Excercise at a value of $85 009), Robin C. Kramer (Option Excercise at a value of $175 158), Susan H. Alexander (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (39.29 %)
10 (34.48 %)
11 (36.67 %)
Moderate Buy
3 (10.71 %)
3 (10.34 %)
2 (6.67 %)
Hold
14 (50.00 %)
16 (55.17 %)
17 (56.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.09
Moderate Buy
2.19
Moderate Buy
2.18

Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

CEO: Michel Vounatsos

Telephone: +1 617 679-2000

Address: 225 Binney Street, Cambridge 02142, MA, US

Number of employees: 9 100

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

61%39%

Bearish Bullish

62%38%

Bearish Bullish

59%41%

TipRanks News for BIIB

Thu, 12 May 2022 16:38 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB) and Altimmune (ALT)

- TipRanks. All rights reserved.

Wed, 04 May 2022 10:26 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Veracyte (VCYT) and Kala Pharmaceuticals (KALA)

- TipRanks. All rights reserved.

Sat, 30 Apr 2022 03:54 GMT Biogen (BIIB) Receives a Hold from Robert W. Baird

- TipRanks. All rights reserved.

Sat, 09 Apr 2022 03:15 GMT Biogen (BIIB) Receives a Buy from Leerink Partners

- TipRanks. All rights reserved.

Fri, 08 Apr 2022 16:14 GMT Biogen Wavers as Aduhelm Support Wanes

- TipRanks. All rights reserved.

Wed, 06 Apr 2022 01:55 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Biogen (BIIB) and Pacira Pharmaceuticals (PCRX)

- TipRanks. All rights reserved.

Mon, 21 Mar 2022 15:15 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), Knight Therapeutics (OtherKHTRF) and Mersana Therapeutics (MRSN)

- TipRanks. All rights reserved.

Mon, 21 Feb 2022 18:32 GMT Biogen: Alzheimers Treatment Could Be a Great Success

- TipRanks. All rights reserved.

Sat, 12 Feb 2022 09:06 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Becton Dickinson (BDX), Biogen (BIIB) and AmerisourceBergen (ABC)

- TipRanks. All rights reserved.

Fri, 04 Feb 2022 09:24 GMT Biogen Delivers Mixed Q4 Results Shares Hit All-Time Low

- TipRanks. All rights reserved.

Thu, 03 Feb 2022 16:55 GMT Biogen Slips as Drug Sales Prove Tepid

- TipRanks. All rights reserved.

Thu, 03 Feb 2022 13:25 GMT Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), Adicet Bio (ACET)

- TipRanks. All rights reserved.

Fri, 21 Jan 2022 15:47 GMT Biogen: Promising Pipeline, Needs Catalysts as Profitability Weakens

- TipRanks. All rights reserved.

Fri, 21 Jan 2022 01:45 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), UnitedHealth (UNH) and Molecular Partners AG (OtherMLLCF)

- TipRanks. All rights reserved.

Thu, 20 Jan 2022 17:36 GMT Biogen: Alzheimers Treatment Has a Bad Start

- TipRanks. All rights reserved.

Fri, 14 Jan 2022 13:05 GMT Analysts Top Healthcare Picks: Biogen (BIIB), Zoetis (ZTS)

- TipRanks. All rights reserved.

Thu, 13 Jan 2022 06:55 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Masimo (MASI) and Beyondspring (BYSI)

- TipRanks. All rights reserved.

Thu, 13 Jan 2022 06:45 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Incyte (INCY) and InflaRx (IFRX)

- TipRanks. All rights reserved.

Tue, 11 Jan 2022 11:55 GMT Biogen (BIIB) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Thu, 06 Jan 2022 16:25 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Biogen (BIIB) and Pacira Pharmaceuticals (PCRX)

- TipRanks. All rights reserved.

Sun, 02 Jan 2022 09:27 GMT Biogen Blasts Up, Plunges on Samsung Rumors

- TipRanks. All rights reserved.

News

Stocktwits